Bioinformatics analysis of immune-programmed cell death-related genes in nasopharyngeal carcinoma

Abstract

Background: Nasopharyngeal carcinoma (NPC) is a prevalent malignant tumor of the head and neck, characterized by a complex pathogenesis. Most newly diagnosed NPC patients are locally advanced, and 20%–30% of advanced NPC patients have poor immunotherapy results.

Purpose: This study aimed to identify key genes associated with immunity and programmed cell death (PCD) in NPC, thereby providing new targets and strategies for precision treatment.

Results: In this study, functional annotation and pathway enrichment analysis of differentially expressed genes (DEGs) of GSE12452 and GSE61218 was performed using Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG). Moreover, the search tool for the retrieval of interaction gene/proteins database was constructed to establish a protein-protein interaction (PPI) network to screen key genes. From GSE12452 and GSE61218, 700 and 619 DEGs were obtained, respectively, and 346 common differential expressed genes (co-DEGs) were screened. Furthermore, 24 immune-related common differential expressed genes (IDEGs) were screened by the interaction of co-DEGs with immune-related DEGs. The major GO functions enriched for IDEGs were chemokine activity and receptor binding, and KEGG pathways were enriched for cytokine-cytokine receptor interactions, IL-17 signaling pathway, chemokine signaling pathway, and so on. PPI analysis identified seven hub genes, including interferon-gamma (IFNG), CXCL11, CCL8, IL33, Prostaglandin-endoperoxide synthase 2 (PTGS2), CXCL3, and CXCL14. Remarkably, IFNG and PTGS2 may be the key targets for PCD regulation of NPC immunity.

Conclusion: Our results suggest that IFNG and PTGS2 are expected to be new markers and targets for the diagnosis and treatment of NPC, which opens a new way to further improve the prognosis of NPC patients.

Keywords

nasopharyngeal carcinoma / programmed cell death / tumor immune

References

[1] Bray F , Laversanne M , Sung H . Global cancer statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2024; 74 (3): 229- 263.

[2] Chen YP , Chan ATC , Le QT , Blanchard P , Sun Y , Ma J . Nasopharyngeal carcinoma. Lancet. 2019; 394 (10192): 64- 80.

[3] Mao YP , Xie FY , Liu LZ . Re-evaluation of the 6th edition of AJCC staging system for nasopharyngeal carcinoma and proposed improvement based on magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 2009; 73 (5): 1326- 1334.

[4] Sun Y , Li WF , Chen NY . Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A Phase 3, Multicentre, Randomized Controlled Trial. Lancet Oncol. 2016; 17 (11): 1509- 1520.

[5] Zhang Y , Chen L , Hu GQ . Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. N Engl J Med. 2019; 381 (12): 1124- 1135.

[6] Yang Y , Pan J , Wang H . Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic Nasopharyngeal carcinoma: A Multicenter Phase 3 Trial (RATIONALE-309). Cancer Cell. 2023; 41 (6): 1061- 1072.e4.

[7] Yang Y , Qu S , Li J . Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st):A Multicentre, Randomised, Double-Blind, Phase 3 Trial. Lancet Oncol. 2021; 22 (8): 1162- 1174.

[8] Mai HQ , Chen QY , Chen D . Toripalimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: The JUPITER-02 Randomized Clinical Trial. JAMA. 2023; 330 (20): 1961- 1970.

[9] Ma J , Sun Y , Liu X , et al. PD-1 blockade with sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC):A Multicenter Phase 3 Randomized Controlled Trial (CONTINUUM). J Clin Oncol. 2023; 41 (17 Suppl l l): LBA6002.

[10] Liu H , Tang L , Li Y . Nasopharyngeal carcinoma: Current Views on the Tumor Microenvironment's Impact on Drug Resistance and Clinical Outcomes. Mol Cancer. 2024; 23 (1): 20.

[11] Bertheloot D , Latz E , Franklin BS . Necroptosis, pyroptosis and apoptosis: An Intricate Game of Cell Death. Cell Mol Immunol. 2021; 18 (5): 1106- 1121.

[12] Liu J , Hong M , Li Y , Chen D , Wu Y , Hu Y . Programmed cell death tunes tumor immunity. Front Immunol. 2022; 13: 847345.

[13] Wendlocha D , Kubina R , Krzykawski K , Mielczarek-Palacz A . Selected flavonols targeting cell death pathways in cancer therapy: The Latest Achievements in Research on Apoptosis, Autophagy, Necroptosis, Pyroptosis, Ferroptosis, and Cuproptosis. Nutrients. 2024; 16 (8): 1201.

[14] Sun LL , Linghu DL , Hung MC . Ferroptosis: A Promising Target for Cancer Immunotherapy. Am J Cancer Res. 2021; 11 (12): 5856- 5863.

[15] Park HH , Kim HR , Park SY . RIPK3 activation induces TRIM28 derepression in cancer cells and enhances the anti-tumor microenvironment. Mol Cancer. 2021; 20 (1): 107.

[16] Tan Y , Zhou J , Liu K . Novel prognostic biomarkers in nasopharyngeal carcinoma unveiled by mega-data bioinformatics analysis. Front Oncol. 2024; 14: 1354940.

[17] Tai J , Park J , Han M , Kim TH . Screening key genes and biological pathways in nasopharyngeal carcinoma by Integrated bioinformatics analysis. Int J Mol Sci. 2022; 23 (24): 15701.

[18] Hu Y , Liu Y , Zong L . The multifaceted roles of GSDMEmediated pyroptosis in cancer: Therapeutic Strategies and Persisting Obstacles. Cell Death Dis. 2023; 14 (12): 836.

[19] Young TM , Reyes C , Pasnikowski E . Autophagy protects tumors from T cell-mediated cytotoxicity via inhibition of TNFα-induced apoptosis. Sci Immunol. 2020; 5 (54): eabb9561.

[20] Wang W , Green M , Choi JE . CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy. Nature. 2019; 569 (7755): 270- 274.

[21] Lin J , Sun S , Zhao K . Oncolytic Parapoxvirus induces Gasdermin E-mediated pyroptosis and activates antitumor immunity. Nat Commun. 2023; 14 (1): 224.

[22] Gresser I , et al. Biologic effects of interferons. J Invest Dermatol. 1990; 95 (6 suppl l l): 66S71S.

[23] Han J , Wu M , Liu Z . Dysregulation in IFN-γ signaling and response: The Barricade to Tumor Immunotherapy. Front Immunol. 2023; 14: 1190333.

[24] Tanaka R , Ichimura Y , Kubota N . Differential involvement of programmed cell death ligands in skin immune responses. J Invest Dermatol. 2022; 142 (1): 145- 154.e8.

[25] Ren J , Li N , Pei S . Histone methyltransferase WHSC1 loss dampens MHC-I antigen presentation pathway to impair IFN-γ-stimulated antitumor immunity. J Clin Investig. 2022; 132 (8): e153167.

[26] Yang X , Zuo X , Zeng H . IFN-Γ facilitates corneal epithelial cell pyroptosis through the JAK2/STAT1 pathway in dry eye. Investig Ophthalmol Vis Sci. 2023; 64 (3): 34.

[27] Fang C , Weng T , Hu S . IFN-γ-induced ER stress impairs autophagy and triggers apoptosis in lung cancer cells. OncoImmunology. 2021; 10 (1): 1962591.

[28] Gong Z , Li Q , Shi J . Lung fibroblasts facilitate pre-metastatic niche formation by remodeling the local immune microenvironment. Immunity. 2022; 55 (8): 1483- 1500.e9.

[29] Chen Y , Chen HN , Wang K . Ketoconazole exacerbates mitophagy to induce apoptosis by downregulating cyclooxygenase-2 in hepatocellular carcinoma. J Hepatol. 2019; 70 (1): 66- 77.

RIGHTS & PERMISSIONS

The Author(s). Eye & ENT Research published by John Wiley & Sons Australia, Ltd on behalf of Higher Education Press.